New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
12:33 EDTINOInovio prepping for failure of cervical cancer vaccine study, TheStreet says
With results due "any day" from Inovio Pharmaceuticals' phase II study of its vaccine for cervical pre-cancerous lesions, the company's CEO is "walking back expectations" and "laying the foundation for a massive spin job," according to TheStreet's Adam Feuerstein. The author said he suspects Inovio already has data in hand and that recent "red flags" by CEO Joseph Kim and the company may be intended to "cushion the vaccine's failure." Reference Link
News For INO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
08:01 EDTINOInovio volatility low into CDC confirms first U.S. Ebola case in Texas
Inovio overall option implied volatility of 57 compares to its 26-week average of 102 according to Track Data, suggesting decreasing price movement into CDC confirms the first U.S. Ebola case in Texas.
September 26, 2014
07:32 EDTINOBioCentury to hold a conference
21st Annual NewsMakers in the Biotech Industry Conference to be held in New York on September 26.
September 24, 2014
06:02 EDTINOInovio Ebola vaccine moving into human trial with GeneOne Life Science
Subscribe for More Information
September 22, 2014
08:10 EDTINOInovio initiates phase I clinical trial in patients with aerodigestive cancers
Inovio announced it has initiated a phase I clinical trial in patients with aerodigestive cancers. The trial will evaluate the safety, tolerability, and immunogenicity of INO-3106. This immunotherapy targets human papillomavirus type 6, which causes most aerodigestive cancers. This study is part of Inovio's strategy to broadly expand clinical development of its DNA-based immune therapy products to treat different HPV types and the many diseases they cause. It is a phase I, open label compassionate study enrolling patients with invasive cancer who have exhausted all other treatment options. The study will test Inovio's immunotherapy, INO-3106, alone or in combination with DNA-based IL-12, Inovio's proprietary immune activator, in subjects with HPV-6 associated aerodigestive malignancies. Successful results could open a path to pursuing an FDA orphan designation for aerodigestive cancers.
September 19, 2014
10:53 EDTINO Options with increasing implied volatility: ESI INO VALE AGNC
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use